Texas’ lawsuit against Johnson & Johnson for its off-label marketing of Risperdal, which the state alleges involved fraudulent claims about the drug’s safety and effectiveness, begins today. This case promises to reveal much about the financial relationships between J&J and the academic psychiatrists who promoted the use of Risperdal to Medicaid patients.
Read more Discuss →
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.